Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficientl...

Full description

Saved in:
Bibliographic Details
Main Authors: Diego Orsini, Giacomo Caldarola, Annunziata Dattola, Elena Campione, Nicoletta Bernardini, Pasquale Frascione, Clara De Simone, Antonio G. Richetta, Marco Galluzzo, Nevena Skroza, Chiara Assorgi, Emanuele Amore, Gennaro M. Falco, Ruslana Gaeta Shumak, Fabio Artosi, Giulia Maretti, Concetta Potenza, Luca Bianchi, Giovanni Pellacani, Ketty Peris, Claudio Bonifati, Dario Graceffa
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Tildrakizumab
immunomodulatory therapies
biologics
psoriasis
psoriasis treatment
anti-IL-23-biologics
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2319304
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficiently explored. We conducted this real-life retrospective multicentric observational study to assess the effectiveness of tildrakizumab in elderly patients with moderate-to-severe psoriasis, with involvement of difficult-to-treat areas.Materials and methods: We enrolled forty-nine patients aged 65 years old or more (mean age 73.1 ± 6.0), all treated with tildrakizumab for at least 28 weeks. The effectiveness of tildrakizumab was assessed by Static Physician’s Global Assessment of Genitalia (sPGA-G), fingernail-PGA (f-PGA), palmoplantar PGA (pp-PGA), scalp-specific PGA (sc-PGA), and Psoriasis Area and Severity Index (PASI) scores.Results: Significant improvements in PASI scores were observed within 28 weeks of treatment, with 77.5%, 60%, and 45.2% of patients achieving PASI75, PASI90, and PASI100, respectively. The mean PASI decreased significantly from baseline (13.6 ± 9.9) to 1.3 ± 1.7 at week 28. More than 90% of patients had clear sPGA-G and pp-PGA scores and over 70% had clear f-PGA and sc-PGA scores after 28 weeks.Conclusions: Our findings suggest that tildrakizumab could be a valuable option for the treatment of elderly patients, including those with difficult-to-treat areas involvement.
ISSN:0954-6634
1471-1753

Similar Items